PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of plosonePLoS OneView this ArticleSubmit to PLoSGet E-mail AlertsContact UsPublic Library of Science (PLoS)
 
PLoS One. 2011; 6(12): e29283.
Published online Dec 27, 2011. doi:  10.1371/journal.pone.0029283
PMCID: PMC3246458
Catechol-O-Methyltransferase Val158Met Polymorphism Associates with Individual Differences in Sleep Physiologic Responses to Chronic Sleep Loss
Namni Goel,1* Siobhan Banks,1¤ Ling Lin,2 Emmanuel Mignot,2 and David F. Dinges1
1Division of Sleep and Chronobiology, Department of Psychiatry, School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America
2Center for Narcolepsy, Department of Psychiatry and Behavioral Sciences, Howard Hughes Medical Institute, Stanford University, California, United States of America
Monica Uddin, Editor
Wayne State University, United States of America
* E-mail: goel/at/mail.med.upenn.edu.
Conceived and designed the experiments: NG DD. Performed the experiments: SB. Analyzed the data: NG. Contributed reagents/materials/analysis tools: EM LL. Wrote the paper: NG.
¤Current address: Centre for Sleep Research, University of South Australia, Adelaide, South Australia, Australia
Received January 14, 2011; Accepted November 23, 2011.
Background
The COMT Val158Met polymorphism modulates cortical dopaminergic catabolism, and predicts individual differences in prefrontal executive functioning in healthy adults and schizophrenic patients, and associates with EEG differences during sleep loss. We assessed whether the COMT Val158Met polymorphism was a novel marker in healthy adults of differential vulnerability to chronic partial sleep deprivation (PSD), a condition distinct from total sleep loss and one experienced by millions on a daily and persistent basis.
Methodology/Principal Findings
20 Met/Met, 64 Val/Met, and 45 Val/Val subjects participated in a protocol of two baseline 10h time in bed (TIB) nights followed by five consecutive 4 h TIB nights. Met/Met subjects showed differentially steeper declines in non-REM EEG slow-wave energy (SWE)—the putative homeostatic marker of sleep drive—during PSD, despite comparable baseline SWE declines. Val/Val subjects showed differentially smaller increases in slow-wave sleep and smaller reductions in stage 2 sleep during PSD, and had more stage 1 sleep across nights and a shorter baseline REM sleep latency. The genotypes, however, did not differ in performance across various executive function and cognitive tasks and showed comparable increases in subjective and physiological sleepiness in response to chronic sleep loss. Met/Met genotypic and Met allelic frequencies were higher in whites than African Americans.
Conclusions/Significance
The COMT Val158Met polymorphism may be a genetic biomarker for predicting individual differences in sleep physiology—but not in cognitive and executive functioning—resulting from sleep loss in a healthy, racially-diverse adult population of men and women. Beyond healthy sleepers, our results may also provide insight for predicting sleep loss responses in patients with schizophrenia and other psychiatric disorders, since these groups repeatedly experience chronically-curtailed sleep and demonstrate COMT-related treatment responses and risk factors for symptom exacerbation.
The catechol-O-methyltransferase (COMT) valine158methionine (Val158Met) polymorphism, replaces valine (Val) with methionine (Met) at codon 158 of the COMT protein. As a result of this common substitution, activity of the COMT enzyme, which modulates dopaminergic catabolism in the prefrontal cortex (PFC), is reduced 3-to-4-fold in COMT Met carriers compared with Val carriers, translating into more dopamine availability at the receptors and higher cortical dopamine concentrations [1]. This COMT polymorphism functionally predicts less efficient PFC functioning and poor working memory performance on some tasks in healthy subjects [2][5] and in patients with schizophrenia [1][4], [6] (but see [7]), carrying the high-activity Val allele.
In healthy men, the COMT Val158Met polymorphism has been associated with sleep physiology. In acute total sleep deprivation (TSD), in which an entire night of sleep is lost, the polymorphism predicted interindividual differences in brain alpha oscillations in wakefulness and 11–13 Hz EEG activity in wakefulness, rapid-eye movement (REM) and non-REM sleep [8]. It also modulated the effects of the wake-promoting drug modafinil on subjective well-being, sustained vigilant attention and executive functioning, and on 3.0–6.75 Hz and >16.75 Hz activity in non-REM sleep, but was not associated with subjective sleepiness, slow-wave activity or slow-wave sleep changes in recovery sleep following TSD or at baseline [9], [10].
In sleep and neurodegenerative disorders, the COMT Val158Met polymorphism also has been linked to daytime sleepiness. Val/Val female patients with narcolepsy fell asleep two times faster than the Val/Met or Met/Met genotypes during the Multiple Sleep Latency Test (MSLT) while the opposite was true for males [11]. In addition, Met/Met patients with narcolepsy showed more sleep onset REM periods during the MSLT while Val/Val subjects showed less sleep paralysis [11] and were more responsive to modafinil's stimulating effects [12]. Met/Met and Val/Met patients with Parkinson's disease demonstrated higher subjective daytime sleepiness than Val/Val subjects [13], although a larger study failed to confirm this finding [14].
Beyond its relationship to sleep and to cognitive function, the COMT Val158Met polymorphism has been linked to psychiatric conditions. This polymorphism has been associated with susceptibility to schizophrenia [1], [15] and bipolar disorder [16][18] and also has been associated with other mood disorders including major depressive disorder, obsessive compulsive disorder, eating disorders and panic and anxiety disorders [1], [19], [20]. Importantly, this COMT polymorphism predicted behaviors in healthy adults which tie to psychiatric disorders [2], [3]—thus, investigation of this genotype in healthy individuals has applications for clinical research.
Considering the aforementioned literature, we hypothesized that COMT would be a novel genetic biomarker in healthy adult sleepers of differential vulnerability to sleep homeostatic, sleepiness and neurobehavioral responses during chronic PSD. Chronic PSD is a condition representative of real world situations, experienced by millions on a consecutive and persistent basis, and associated with serious health consequences [21]. In addition, chronic PSD is similar to the sleep-wake patterns found in schizophrenia—and in bipolar disorder and other mood disorders—whereby patients experience repeatedly curtailed or fragmented sleep rather than lose an entire night of sleep [22]. Thus, as an ancillary objective, we investigated responses to such PSD conditions in healthy adults as a putative experimental model for predicting sleep, alertness and cognitive responses to sleep loss in patients with psychiatric disorders.
Ethics Statement
The protocols described below were approved by the Institutional Review Board of the University of Pennsylvania. After complete description of the study, and prior to study entry, written informed consent was obtained from all subjects according to the principles expressed in the Declaration of Helsinki; all subjects received compensation for participation.
Participants
One hundred and twenty-nine subjects participated in one of two chronic PSD experiments (described below). Following protocol completion, subjects were genotyped for the COMT Val158Met polymorphism. This was a retrospective analysis; thus, COMT genotypes were not matched. The COMT Val158Met genotypic and allelic frequencies for whites and African Americans (Table 1) approximated those reported in other studies using mixed ethnicity samples [23].
Table 1
Table 1
Characteristics of Met/Met, Val/Met and Val/Val Subjects (Mean ± SD).
Subjects met the following inclusionary criteria, as detailed in [24]: age between 22–45 yrs.; physically and psychologically healthy, as assessed by physical examination and history; no clinically significant blood chemistry abnormalities; drug-free urine samples; good habitual sleep, between 6.5–8.5 h daily duration with regular bedtimes, and wake-up times between 0600–0900 h (verified by sleep logs and wrist actigraphy for ≥one week before study entry); absence of extreme morningness/eveningness; absence of sleep or circadian disorders, assessed by questionnaire and polysomnography; absence of psychiatric illness or adverse neuropsychiatric reaction to sleep deprivation; no alcohol or drug abuse history; no current use of medical or drug treatments (excluding oral contraceptives).
Experimental Design
Subjects participated in an 11- or 16-day experiment in the Sleep and Chronobiology Laboratory at the Hospital of the University of Pennsylvania. Only data from the first seven nights of the protocols—which were procedurally identical—were analyzed. On the two baseline nights, subjects received 10 h time in bed (TIB) from 2200–0800 h to reduce any pre-existing sleep debt; on the subsequent five nights, subjects received 4 h TIB (0400–0800 h).
During the protocol, laboratory conditions and scheduled activities were highly controlled. Ambient light remained at <50 lux during wakefulness, and at <1 lux (darkness) during sleep. Temperature was maintained at 22±1°C. Subjects were continuously monitored by trained staff. Between performance bouts, they were restricted from strenuous activities or having visitors, but could read, play games, watch movies, and interact with staff to help remain awake. Subjects received three standardized meals per day and an optional evening snack. Caffeine, turkey, bananas, alcohol and tobacco were prohibited.
Neurobehavioral Assessments
Subjects performed a computerized neurobehavioral test battery every 2 h during wakefulness, as detailed in [24], which included: the Karolinska Sleepiness Scale (KSS), a Likert-type subjective sleepiness scale; a visual analog scale of fatigue (VAS) anchored by “fresh as a daisy” and “tired to death”; the Profile of Mood States (POMS), a scale assessing transient affective states; the Digit Symbol Substitution Task (DSST), a cognitive throughput task; the Digit Span (DS) task, a working memory storage capacity test, given in forward and backward versions and summed as a total number correct measure; and the Psychomotor Vigilance Task (PVT), a sustained attention test utilizing reaction times as a behavioral alertness assay. Subjects remained seated throughout testing, were behaviorally monitored, and were instructed to perform to the best of their ability and use compensatory effort to maintain performance. Baseline values were derived from the second baseline day (B2). Daily values for each performance task were calculated by averaging scores from all test bouts that day.
Other Measurements
Before the study, subjects completed questionnaires on demographic, clinical sleepiness, sleep–wake and circadian-related variables, and psychosocial/personality traits, as detailed in [24], including the Epworth Sleepiness Scale, the Morningness-Eveningness Composite Scale, the Beck Depression Inventory, the Eysenck Personality Inventory and the North American Adult Reading Test. At partial sleep deprivation/restriction night 5 (SR5), four standardized executive function tests were administered: the Hayling and Brixton tests, the Controlled Oral Word Association Test, and the Tower of London. In the 11-day protocol, a modified Maintenance of Wakefulness Test (MWT) [25]—a physiological measure of the ability to resist sleep—was administered at B2 and SR5 (a single trial was conducted between 1430–1600 h) using a standard recording montage. Before each trial, the lights were dimmed to <10 lux and subjects were instructed to “keep your eyes open and try not to fall asleep”. Each trial was terminated at the first microsleep (10 seconds of theta activity) [25] determined by the C3/A2 derivation or at 30 minutes if sleep onset did not occur. MWT scores represented either the time (minutes) to microsleep initiation or 30 minutes (if no microsleep occurred).
Sleep Architecture
Polysomnography
The polysomnographic (PSG) montage included frontal (Fz), central (C3), and occipital (O2) EEG, bilateral EOG, submental EMG, and ECG. Data were recorded from 2200–0800 h on B2, and from 0400–0800 h on partial sleep deprivation/restriction night 1 (SR1) and SR5. Records were visually scored in 30-second epochs using standard scoring criteria by a trained scorer blind to COMT typing.
EEG Analysis
After visually determined artifact rejection, the EEG was sampled at 128 Hz and spectral analysis of 3 sleep EEG derivations (C3/A2; Fz/A1; O2/A1) was performed with Fast Fourier Transform averaged across consecutive 30-second epochs (average of 6 5-second epochs, resulting in a frequency resolution of 0.2 Hz). We chose to examine the C3, Fz and O2 derivations, since we have found differential genotype changes in these derivations in prior studies [24]. For each night, slow-wave energy (SWE) in the delta band (0.5–4.5 Hz) was totaled over all epochs of non-REM (visually-scored stages 2–4) sleep. Power in the delta band (SWA) was calculated by dividing SWE by the number of non-REM sleep epochs. For B2, absolute values were determined for each hour of sleep for SWE and SWA; for SR1 and SR5, SWE and SWA were normalized by calculating the percent of the corresponding B2 hour. For some records, EEG signal quality was insufficient or contained too much artifact for reliable power spectral analysis (Figures 1 and and2).2). Although the delta band was of primary interest, we also examined other frequency bands in both non-REM and REM sleep which were defined as follows: theta (4.5–8 Hz), alpha (8–12 Hz), sigma (12–14 Hz), and beta (14–30 Hz).
Figure 1
Figure 1
Hourly slow-wave energy (SWE) and slow-wave activity (SWA) during baseline for the COMT Val158Met genotypes.
Figure 2
Figure 2
Slow-wave activity (SWA) and slow-wave energy (SWE) during sleep deprivation for the COMT Val158Met genotypes.
Genotyping
Genomic DNA was extracted from whole blood using Qiagen's QIAamp DNA Blood Mini Kit (Catalog #51106). COMT genotypes were determined by PCR-RFLP analysis. A G-to-A substitution at codon 158 encoding valine or methionine generates this polymorphism. The target sequence was PCR-amplified and the product was digested by the restriction enzyme Nla III and electrophoresed in an 8% polyacrylamide gel to detect the two alleles, as described in [26].
Statistical Analyses
Mixed model analyses of covariance (ANCOVA), with day or hour as the within-subjects (repeated measures) factor, genotype as the between-group factor, and ethnicity as a covariate, were used to analyze MWT, PSG, EEG, PVT, KSS, VAS, POMS, DSST and DS data. Greenhouse–Geisser corrections were applied to all within-subjects effects. One-way ANCOVA, with ethnicity as a covariate, were used to analyze demographic and pre-study measures, PSG, MWT and cognitive, executive function and sleep measures during baseline and chronic PSD. In separate analyses, gender was investigated as an additional factor because of previous findings [11]; however, no significant gender differences were found. Post-hoc comparisons using Bonferroni-adjusted probabilities examined significant group differences for all measures. SPSS version 15.0 (SPSS Inc., Chicago, IL) was used for statistical analyses; p≤0.05 was considered significant.
Demographic and Pre-study Variables
There were Met/Met genotypic differences (χ2 = 9.48, p = 0.002) and Met allelic differences (χ2 = 8.43, p = 0.004) between whites and African Americans (Table 1); therefore, ethnicity was statistically controlled for as a covariate in all analyses. Met/Met and Val/Met individuals had higher IQ scores than Val/Val subjects (Table 1), although the groups did not differ significantly in other demographic variables including age, body mass index, or sex. Moreover, the groups did not show differences in psychosocial/personality traits, pre-study sleep variables, clinical sleepiness or circadian phase markers (Morningness-Eveningness chronotype and sleep midpoint).
Sleep Physiology
Non-REM EEG Slow-Wave Energy and Slow-Wave Activity
Across B2, the genotypes did not differ in SWE or SWA calculated from the C3 (Figure 1A, 1B; SWE: F2,88 = 1.12, p = 0.332; SWA: F2,88 = 0.55, p = 0.577), Fz (Figure 1C, 1D; SWE: F2,94 = 0.22, p = 0.801; SWA: F2,94 = 0.31, p = 0.737) and O2 (Figure 1E, 1F; SWE: F2,97 = 0.61, p = 0.545; SWA: F2,97 = 0.58, p = 0.561) EEG derivations. SWE and SWA dissipated across B2 for the C3 (SWE: F3.36,295.63 = 38.40, p<0.0001; SWA: F3.02,265.85 = 36.51, p<0.0001), Fz (SWE: F2.41,226.56 = 18.16, p<0.0001; SWA: F1.92,180.49 = 11.63, p<0.0001) and O2 channels (SWE: F1.97,190.58 = 15.13, p<0.0001; SWA: F1.85,179.55 = 13.19, p<0.0001), but not in a differential pattern across genotypes (C3 SWE: F6.72, 295.63 = 0.93, p = 0.480; C3 SWA: F6.04,265.85 = 0.76, p = 0.603; Fz SWE: F4.82,226.56 = 0.57, p = 0.720; Fz SWA: F3.84,180.49 = 0.76, p = 0.550; O2 SWE: F3.93,190.58 = 0.47, p = 0.754; O2 SWA: F3.70,179.55 = 0.45, p = 0.758).
SWE and SWA displayed acute responses to PSD in all groups—evidenced by percentage increases above the corresponding B2 hour in all channels. SWE% baseline showed a differential change across PSD for the COMT genotypes in the Fz derivation (Figure 2C; F4.55,213.81 = 2.57, p = 0.032), but not in Fz SWA% baseline (Figure 2D; F3.48,165.39 = 2.11, p = 0.092) with Met/Met subjects showing sharper dissipation of SWE from hour 1 to hour 2 on SR1 and SR5. By contrast, neither SWA% baseline nor SWE% baseline in the C3 (Figure 2A, 2B; SWA% baseline: F4.19,201.25 = 0.86, p = 0.490; SWE% baseline: F3.76,180.25 = 1.25, p = 0.294) or O2 EEG derivations showed significant differential changes across chronic PSD (Figure 2E, 2F; SWA% baseline: F4.25,197.47 = 0.72, p = 0.589; SWE% baseline: F4.52,212.28 = 0.75, p = 0.574).
SWA% baseline and SWE% baseline derived from Fz increased across PSD (Figure 2C, 2D; SWA% baseline: F1.74,165.39 = 3.93, p = 0.027; SWE% baseline: F2.28,213.81 = 4.08, p = 0.014), as did SWA% baseline derived from C3 (Figure 2B; F2.10,201.25 = 3.13, p = 0.044), while no other measures were significant (Figure 2A, 2E, 2F; SWE C3% baseline: F1.88,180.25 = 1.80, p = 0.171; SWE O2% baseline: F2.26,212.28 = 2.32, p = 0.094; SWA O2% baseline: F2.12,197.47 = 1.59, p = 0.205). In addition, the groups did not differ in SWE% baseline (F2,96 = 0.78, p = 0.460) or SWA% baseline (F2,96 = 1.20, p = 0.307) from the C3 (Figure 2A, 2B), Fz (Figure 2C, 2D; SWE% baseline: F2,94 = 0.32, p = 0.727; SWA% baseline: F2,95 = 0.10, p = 0.901) or O2 channels (Figure 2E, 2F; SWE% baseline: F2,94 = 0.84, p = 0.436; SWA% baseline: F2,93 = 1.41, p = 0.248).
Other EEG Frequencies
Although the primary focus of our EEG analyses was on the delta frequency in NREM, as the putative marker of sleep homeostasis, we also examined the other EEG frequency ranges in NREM and in REM sleep at baseline and during sleep restriction for the C3, Fz, and O2 derivations. We failed to find significant genotype differences for any of these measures (all p's>0.05).
Polysomnography
Across B2, SR1 and SR5, Val/Val subjects had more stage 1 sleep (Table 2; duration: F2,99 = 3.15, p = 0.047; %TST: F2,99 = 3.72, p = 0.028, Bonferroni correction, p<0.05). At B2, these subjects had shorter REM sleep latency (F2,113 = 3.07, p = 0.050, Bonferroni correction, p<0.05) and more stage 1 sleep (duration: F2,113 = 3.95, p = 0.022; %TST: F2,113 = 3.30, p = 0.040, Bonferroni correction, p<0.05). This latter difference was maintained at SR1, with Val/Val subjects showing more stage 1 sleep (duration: F2,113 = 5.50, p = 0.005; %TST: F2,113 = 6.16, p = 0.003, Bonferroni correction, p<0.05).
Table 2
Table 2
Polysomnographic Sleep Measures during B2, SR1 and SR5 for Met/Met, Val/Met and Val/Val Subjects (Mean ± SD)
The genotypes showed differential PSG responses to PSD (Table 2). During PSD, Val/Val subjects showed differentially smaller increases in SWS (%TST: F3.92,194.083 = 2.81, p = 0.027) and smaller reductions in stage 2 sleep (%TST: F3.87,191.578 = 2.65, p = 0.036). All genotypes displayed acute responses consistent with sleep loss and with increases in homeostatic drive: sleep efficiency and stages 3 and 4 (slow-wave) sleep significantly increased, while TST, sleep onset latency, WASO, and stages 1 and 2 sleep significantly decreased (Table 2).
Cognitive Performance and Executive Functioning
Chronic PSD induced significant cognitive performance deficits across days as demonstrated by increases in PVT lapses (>500ms reaction times) and in variability for all groups across sleep loss (Figure 3A). Although all genotypes increased lapses across days (F2.45,305.67 = 12.90, p<0.0001), there were no differential responses (F4.89,305.67 = 0.92, p = 0.469) or group differences across days (F2,125 = 0.06, p = 0.941). Moreover, lapses and other PVT measures—errors, fastest 10% and median reaction times, response speed—did not differ across groups during B2 or PSD (all p's>0.05).
Figure 3
Figure 3
Neurobehavioral performance during baseline and chronic partial sleep deprivation for the COMT Val158Met groups.
The groups showed no differential changes in DSST performance across PSD (F5.77,360.44 = 0.50, p = 0.802) nor did scores change across days (F2.88,360.44 = 1.96, p = 0.123) or differ across groups across days (Figure 3B; F2,125 = 0.66, p = 0.521). There were no B2 or PSD group differences in DSST performance (all p's>0.05). Similarly, there were no differential changes in DS total performance across PSD (F5.54,346.18 = 0.67, p = 0.660) or group differences across days (F2,125 = 0.35, p = 0.707) nor did scores change across days (Figure 3C; F2.77,346.18 = 0.88, p = 0.444). Moreover, the groups did not show DS performance differences during B2 or PSD (all p's>0.05).
The Hayling, Brixton, Controlled Oral Word Association Test, and Tower of London—executive function tests measured at SR5—showed no significant differences across the COMT genotypes (all p's>0.05).
Subjective Sleepiness and Fatigue
PSD produced increases in KSS sleepiness (Figure 3D; F3.00,374.85 = 17.94, p<0.0001) and VAS fatigue scores (Figure 3E; F2.48,309.02 = 20.96, p<0.0001) for all genotypes across days. Despite such increased scores across chronic PSD, there were no differential responses in these measures (KSS: F6.00,374.85 = 1.28, p = 0.268; VAS: F4.94,309.02 = 1.68, p = 0.140) or group differences across days (KSS: F2,125 = 0.49, p = 0.615; VAS:F2,125 = 0.15, p = 0.858). Similarly, on an unrelated scale, the Profile of Mood States (POMS), PSD produced increases in subjective fatigue (POMS-F; Figure 3F; F2.34,292.27 = 38.01, p<0.0001) and decreases in vigor (POMS-V; Figure 3G; F2.35,293.41 = 8.79, p<0.0001) across days for all genotypes, but no differential responses (POMS-F: F4.68,292.27 = 1.43, p = 0.217; POMS-V: F4.70,293.41 = 0.66, p = 0.643) or group differences across days for either measure (POMS-F: F2,125 = 2.59, p = 0.079; POMS-V: F2,125 = 0.46, p = 0.632). Moreover, the genotypes did not differ on KSS, VAS, POMS-F or POMS-V scores during B2 or PSD (all p's>0.05).
Physiological Sleepiness
Substantiating the subjective sleepiness data, MWT scores did not differ across groups (F2,86 = 0.12, p = 0.889) or show differential changes to PSD (F2,86 = 0.05, p = 0.951), although all genotypes were less able to resist sleep following deprivation (F1,86 = 4.88, p = 0.030). The groups did not differ on MWT scores at B2 (F2,86 = 0.14, p = 0.936) or SR5 (F2,86 = 0.02, p = 0.882).
The COMT Val158Met polymorphism related to individual differences in sleep homeostatic responses and physiological sleep responses to chronic PSD. Met/Met subjects showed differentially greater declines across days of PSD in NREM EEG SWE—the putative homeostatic marker of sleep drive—compared with Val/Met and Val/Val subjects, despite comparable baseline declines. Val/Val subjects showed differentially smaller SWS increases and smaller reductions in stage 2 sleep during PSD, had more stage 1 sleep across nights, and a shorter baseline REM sleep latency—all indicative of a lower homeostatic drive. The genotypes demonstrated comparable cumulative decreases in cognitive performance, and increases in subjective and physiological sleepiness and fatigue to PSD, with increasing daily inter-subject variability, and showed no executive function performance differences. The COMT Val158Met polymorphism may be a genetic marker for predicting individual differences in sleep homeostasis and physiology, but not in cognitive and executive function responses, resulting from sleep loss in a healthy, racially-diverse population of men and women. Furthermore, these genotype differences in SWE in response to PSD may extend to psychiatric populations; they may relate to treatment response in depression and schizophrenia and may protect against development and exacerbation of psychosis in these disorders.
Under the phenotypic conditions elicited by PSD, Met/Met subjects had significantly larger declines in SWE. Moreover, compared with Val/Val subjects, Met/Met subjects showed significantly less stage 1 sleep and a longer REM sleep latency at baseline and chronic PSD—indicative of a greater sleep homeostatic drive. Since such differences were not observed under basal, fully-rested homeostatic pressure conditions, as was similarly reported in another study [9], Met/Met subjects may possess a greater drive, coupled with a more efficient homeostatic response to sleep loss. Other frequencies, including alpha, which in prior work has shown COMT genotype differences [8], did not show genotype-dependent differences in our study. This finding suggests that the COMT Val158Met polymorphism's influence is likely specific to SWA/SWE and is not due to nonspecific effects of the COMT genotype on EEG-generating mechanisms. Different genes may modulate basal versus evoked homeostatic responses in healthy sleepers; therefore, other markers may influence differential vulnerability in fully-rested conditions.
The COMT polymorphism related to individual differences in sleep homeostatic and physiological responses to chronic PSD, contrasting observations in acute TSD [9]. This difference may be due to the nature of PSD experiments, in which sleep homeostatic mitigation occurs by partial daily sleep recuperation of sleep [27], [28]. Because of this and other reported differences in behavioral and physiological responses to chronic PSD and acute TSD [27], [28], it is possible that specific candidate genes play different roles in the degree of vulnerability and/or resilience to the neurobehavioral and homeostatic effects of these two conditions. In further support of this possibility, we recently found that the PERIOD3 VNTR polymorphism did not relate to individual differences in neurobehavioral performance responses to chronic PSD [24], contrasting data from TSD conditions [29]. Future studies should investigate the distinction between PSD and TSD and the manner in which these conditions relate to phenotype-genotype interactions.
The Met/Met homeostatic response to sleep loss may possibly relate to several recent reports of differential responses to treatment in depression as a function of the COMT Val158Met genotype. For example, this genotype predicted better antidepressant treatment outcome in major depressive disorder [30][32]. Similarly, Benedetti et al. [33] found that bipolar Met/Met patients showed better antidepressant response to the combined chronotherapeutic treatments of sleep deprivation and bright light therapy.
Beyond treatment response, we speculate that the faster dissipation of sleep drive in Met/Met individuals during exposures to sleep loss may mitigate the development of psychotic features of psychiatric disorders. For example, the Met/Met genotype has been related to a reduced risk of experiencing psychotic episodes in bipolar disorder [34] and has been associated with lower severity of delusions in schizophrenia [35]. Whether genotype-related differential responses to sleep loss are important for preventing the development or exacerbation of clinical symptoms is an important area of future investigation in adults with psychiatric disorders.
We found that Met/Met individuals had higher IQ scores than Val/Val individuals, as has been reported previously in the literature [5], [7]. Even after correcting for this IQ difference, we failed to detect differences across genotypes on a variety of executive functioning or cognitive tasks, in contrast to other reports [1]-[4]. We also failed to detect differences in PVT performance at baseline or during PSD, in agreement with findings from a study in TSD [9], [10]. Similarly, we found no DS performance differences across genotypes, in concurrence with other studies in healthy adults [36], [37]. Moreover, a study in TSD conditions reported no genotype differences in the 2-back test or the random number generation task [8] and a recent large study in healthy subjects also failed to find genotype differences [36]. Our negative results extend meta-analytic results indicating the COMT Val158Met polymorphism exerts small effects on executive tasks [7], and support the notion that this polymorphism's role is not generalizable to all cognitive tests or to complex cognitive phenotypes [1], [4], [37].
Met/Met subjects showed higher sleep homeostatic pressure during PSD, but not poorer cognitive, executive functioning or subjective sleepiness responses. Such a separation has been noted previously whereby the homeostatic sleep responses to chronic PSD or to TSD have not been reflected in waking neurobehavioral or cognitive responses [9], [10], [24], [27], [38]. We have yet to identify candidate genes that mediate differential vulnerability to cognitive changes resulting from PSD.
All genotypes showed greater physiological sleepiness, sleep homeostasis, and self-rated sleepiness and fatigue, and poorer cognitive performance across PSD. Thus, PSD produced substantial changes characteristic of cumulative sleep loss, thereby validating our phenotypic approach [24], [27], [28], [38][40].
Even though we utilized a large sample size compared to all other candidate gene studies investigating response to sleep loss in healthy adults [8][10], [29], [41], [42], our findings should be considered preliminary. They serve as a starting point for future—and critical—replication in separate populations.
In addition to the need to replicate our findings, our study has a few limitations. First, we were unable to assess the menstrual cycle phase of our female participants. Second, it is possible that the small but significant genotype difference in REM sleep latency at baseline may affect the relative SWE/SWA values at SR1 and SR5 [43]. Finally, it is possible that genotype differences in NREM-REM sleep cycle lengths [44] may be present during baseline and sleep restriction nights and may influence SWE/SWA hourly values.
In summary, during chronic partial sleep deprivation, Met/Met subjects exhibited faster sleep homeostatic dissipation than Val/Val subjects. The COMT Val158Met polymorphism related to individual differences in sleep homeostatic, but not executive functioning and cognitive responses to chronic PSD, suggesting these measures may be orthogonal and associated with distinct genetic mechanisms. Thus, the COMT Val158Met polymorphism may be a biomarker for predicting differential sleep responses resulting from sleep deprivation in healthy adults and by extension, in various psychiatric populations. We speculate that the sharper dissipation of sleep homeostasis in Met/Met individuals may be protective against the development of psychosis in bipolar depression and schizophrenia, when exposure to sleep loss occurs, and predictive of antidepressant treatment response—these research areas merit further investigation.
Footnotes
Competing Interests: NG is currently an Academic Editor for PLoS ONE (position commenced in July 2010).
Funding: This research was supported by National Space Biomedical Research Institute through National Aeronautics and Space Administration (NASA) (NCC 9-58), National Institutes of Health (NR004281) and Cancer Therapy and Research Center (UL1RR024134) grants awarded to DFD, by the National Institutes of Health (NS-23724) grant to EM and by a grant from the Institute for Translational Medicine and Therapeutics’ (ITMAT) Transdisciplinary Program in Translational Medicine and Therapeutics awarded to NG. The project described was supported in part by grant number UL1RR024134 from the National Center for Research Resources. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Center for Research Resources or the National Institutes of Health. EM is a Howard Hughes Medical Institute Investigator. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
1. Tunbridge EM, Harrison PJ, Weinberger DR. Catechol-o-methyltransferase, cognition, and psychosis: Val158Met and beyond. Biol Psychiatry. 2006;60:141–151. [PubMed]
2. Savitz J, Solms M, Ramesar R. The molecular genetics of cognition: dopamine, COMT and BDNF. Genes Brain Behav. 2006;5:311–328. [PubMed]
3. Egan MF, Goldberg TE, Kolachana BS, Callicott JH, Mazzanti CM, et al. Effect of COMT Val108/158 Met genotype on frontal lobe function and risk for schizophrenia. Proc Natl Acad Sci USA. 2001;98:6917–6922. [PubMed]
4. Dickinson D, Elvevåg B. Genes, cognition and brain through a COMT lens. Neuroscience. 2009;164:72–87. [PMC free article] [PubMed]
5. Barnett JH, Jones PB, Robbins TW, Müller U. Effects of the catechol-O-methyltransferase Val158Met polymorphism on executive function: a meta-analysis of the Wisconsin Card Sort Test in schizophrenia and healthy controls. Mol Psychiatry. 2007;12:502–509. [PubMed]
6. Wirgenes KV, Djurovic S, Sundet K, Agartz I, Mattingsdal M, et al. Catechol O-methyltransferase variants and cognitive performance in schizophrenia and bipolar disorder versus controls. Schizophr Res. 2010;122:31–37. [PubMed]
7. Barnett JH, Scoriels L, Munafò MR. Meta-analysis of the cognitive effects of the catechol-O-methyltransferase gene Val158/108Met polymorphism. Biol Psychiatry. 2008;64:137–144. [PubMed]
8. Bodenmann S, Rusterholz T, Dürr R, Stoll C, Bachmann V, et al. The functional Val158Met polymorphism of COMT predicts interindividual differences in brain α oscillations in young men. J Neurosci. 2009;29:10855–10862. [PubMed]
9. Bodenmann S, Xu S, Luhmann U, Arand M, Berger W, et al. Pharmacogenetics of modafinil after sleep loss: Catechol-O-Methyltransferase genotype modulates waking functions but not recovery sleep. Clin Pharmacol Ther. 2009;85:296–304. [PubMed]
10. Bodenmann S, Landolt HP. Effects of modafinil on the sleep EEG depend on Val158Met genotype of COMT. Sleep. 2010;33:1027–1035. [PubMed]
11. Dauvilliers Y, Neidhart E, Lecendreux M, Billiard M, Tafti M. MAO-A and COMT polymorphisms and gene effects in narcolepsy. Mol Psychiatry. 2001;6:367–372. [PubMed]
12. Dauvilliers Y, Neidhart E, Billiard M, Tafti M. Sexual dimorphism of the catechol-O-methyltransferase gene in narcolepsy is associated with response to modafinil. Pharmacogenomics J. 2002;2:65–68. [PubMed]
13. Frauscher B, Högl B, Maret S, Wolf E, Brandauer E, et al. Association of daytime sleepiness with COMT polymorphism in patients with parkinson disease: a pilot study. Sleep. 2004;27:733–736. [PubMed]
14. Rissling I, Frauscher B, Kronenberg F, Tafti M, Stiasny-Kolster K, et al. Daytime sleepiness and the COMT val158met polymorphism in patients with Parkinson disease. Sleep. 2006;29:108–111. [PubMed]
15. Harrison PJ, Weinberger DR. Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence. Mol Psychiatry. 2005;10:40–68. [PubMed]
16. Zhang Z, Lindpaintner K, Che R, He Z, Wang P, et al. The Val/Met functional polymorphism in COMT confers susceptibility to bipolar disorder: evidence from an association study and a meta-analysis. Neural Transm. 2009;116:1193–1200. [PubMed]
17. Craddock N, Davé S, Greening J. Association studies of bipolar disorder. Bipolar Disord. 2001;3:284–298. [PubMed]
18. Li T, Vallada H, Curtis D, Arranz M, Xu K, et al. Catechol-O-methyltransferase Val158Met polymorphism: frequency analysis in Han Chinese subjects and allelic association of the low activity allele with bipolar affective disorder. Pharmacogenetics. 1997;7:349–353. [PubMed]
19. Ohara K, Nagai M, Suzuki Y, Ohara K. Low activity allele of catechol-o-methyltransferase gene and Japanese unipolar depression. Neuroreport. 1998;9:1305–1308. [PubMed]
20. Mikołajczyk E, Grzywacz A, Samochowiec J. The association of catechol-O-methyltransferase genotype with the phenotype of women with eating disorders. Brain Res. 2010;1307:142–148. [PubMed]
21. Goel N, Rao H, Durmer JS, Dinges DF. Neurocognitive consequences of sleep deprivation. Semin Neurol. 2009;29:320–339. [PMC free article] [PubMed]
22. Wulff K, Gatti S, Wettstein JG, Foster RG. Sleep and circadian rhythm disruption in psychiatric and neurodegenerative disease. Nat Rev Neurosci. 2010;11:589–599. [PubMed]
23. Al-Hendy A, Salama SA. Catechol-O-methyltransferase polymorphism is associated with increased uterine leiomyoma risk in different ethnic groups. J Soc Gynecol Investig. 2006;13:136–144. [PubMed]
24. Goel N, Banks S, Mignot E, Dinges DF. PER3 polymorphism predicts cumulative sleep homeostatic but not neurobehavioral changes to chronic sleep restriction. PLoS ONE. 2009;4:e5874. [PMC free article] [PubMed]
25. Banks S, Van Dongen HPA, Maislin G, Dinges DF. Neurobehavioral dynamics following chronic sleep restriction: Dose-response effects of one night for recovery. Sleep. 2010;33:1013–1026. [PubMed]
26. Lachman HM, Papolos DF, Saito T, Yu YM, Szumlanski CL, et al. Human catechol-O-methyltransferase pharmacogenetics: description of a functional polymorphism and its potential application to neuropsychiatric disorders. Pharmacogenetics. 1996;6:243–250. [PubMed]
27. Van Dongen HPA, Maislin G, Mullington JM, Dinges DF. The cumulative cost of additional wakefulness: Dose-response effects on neurobehavioral functions and sleep physiology from chronic sleep restriction and total sleep deprivation. Sleep. 2003;26:117–126. [PubMed]
28. Drake CL, Roehrs TA, Burduvali E, Bonahoom A, Rosekind M, et al. Effects of rapid versus slow accumulation of eight hours of sleep loss. Psychophysiology. 2001;38:979–987. [PubMed]
29. Viola AU, Archer SN, James LM, Groeger JA, Lo JC, et al. PER3 polymorphism predicts sleep structure and waking performance. Curr Biol. 2007;17:613–618. [PubMed]
30. Spronk D, Arns M, Barnett KJ, Cooper NJ, Gordon E. An investigation of EEG, genetic and cognitive markers of treatment response to antidepressant medication in patients with major depressive disorder: A pilot study. J Affect Disord. 2011;128:41–48. [PubMed]
31. Benedetti F, Dallaspezia S, Colombo C, Lorenzi C, Pirovano A, et al. Effect of catechol-O-methyltransferase Val(108/158)Met polymorphism on antidepressant efficacy of fluvoxamine. Eur Psychiatry. 2010;25:476–478. [PubMed]
32. Baune BT, Hohoff C, Berger K, Neumann A, Mortensen S, et al. Association of the COMT val158met variant with antidepressant treatment response in major depression. Neuropsychopharmacology. 2008;33:924–932. [PubMed]
33. Benedetti F, Barbini B, Bernasconi A, Fulgosi MC, Dallaspezia S, et al. Acute antidepressant response to sleep deprivation combined with light therapy is influenced by the catechol-O-methyltransferase Val(108/158)Met polymorphism. J Affect Disord. 2010;121:68–72. [PubMed]
34. Benedetti F, Dallaspezia S, Colombo C, Lorenzi C, Pirovano A, et al. Association between catechol-O-methyltransferase Val(108/158)Met polymorphism and psychotic features of bipolar disorder. J Affect Disord. 2010;125:341–344. [PubMed]
35. Goghari VM, Sponheim SR. Differential association of the COMT Val158Met polymorphism with clinical phenotypes in schizophrenia and bipolar disorder. Schizophr Res. 2008;103:186–191. [PubMed]
36. Dennis NA, Need AC, LaBar KS, Waters-Metenier S, Cirulli ET, et al. COMT val108/158 met genotype affects neural but not cognitive processing in healthy individuals. Cereb Cortex. 2010;20:672–683. [PMC free article] [PubMed]
37. O'Hara R, Miller E, Liao CP, Way N, Lin X, et al. COMT genotype, gender and cognition in community-dwelling, older adults. Neurosci Lett. 2006;409:205–209. [PMC free article] [PubMed]
38. Goel N, Banks S, Mignot E, Dinges DF. DQB1*0602 predicts interindividual differences in physiologic sleep, sleepiness and fatigue. Neurology. 2010;75:1509–1519. [PMC free article] [PubMed]
39. Belenky G, Wesensten NJ, Thorne DR, Thomas ML, Sing HC, et al. Patterns of performance degradation and restoration during sleep restriction and subsequent recovery: a sleep dose-response study. J Sleep Res. 2003;12:1–12. [PubMed]
40. Mollicone DJ, Van Dongen HP, Rogers NL, Banks S, Dinges DF. Time of day effects on neurobehavioral performance during chronic sleep restriction. Aviat Space Environ Med. 2010;81:735–744. [PubMed]
41. Rétey JV, Adam M, Khatami R, Luhmann UF, Jung HH, et al. A genetic variation in the adenosine A2A receptor gene (ADORA2A) contributes to individual sensitivity to caffeine effects on sleep. Clin Pharmacol Ther. 2007;81:692–698. [PubMed]
42. Groeger JA, Viola AU, Lo JC, von Schantz M, Archer SN, et al. Early morning executive functioning during sleep deprivation is compromised by a PERIOD3 polymorphism. Sleep. 2008;31:1159–1167. [PubMed]
43. Beersma DG, Achermann P. Changes of sleep EEG slow-wave activity in response to sleep manipulations: to what extent are they related to changes in REM sleep latency? J Sleep Res. 1995;4:23–29. [PubMed]
44. Feinberg I, Floyd TC. Systematic trends across the night in human sleep cycles. Psychophysiology. 1979;16:283–91. [PubMed]
Articles from PLoS ONE are provided here courtesy of
Public Library of Science